| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | LATS1 |
| Uniprot No | O95835 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 705-1090aa |
| 氨基酸序列 | FVKIKTLGIGAFGEVCLARKVDTKALYATKTLRKKDVLLRNQVAHVKAERDILAEADNEWVVRLYYSFQDKDNLYFVMDYIPGGDMMSLLIRMGIFPESLARFYIAELTCAVESVHKMGFIHRDIKPDNILIDRDGHIKLTDFGLCTGFRWTHDSKYYQSGDHPRQDSMDFSNEWGDPSSCRCGDRLKPLERRAARQHQRCLAHSLVGTPNYIAPEVLLRTGYTQLCDWWSVGVILFEMLVGQPPFLAQTPLETQMKVINWQTSLHIPPQAKLSPEASDLIIKLCRGPEDRLGKNGADEIKAHPFFKTIDFSSDLRQQSASYIPKITHPTDTSNFDPVDPDKLWSDDNEEENVNDTLNGWYKNGKHPEHAFYEFTFRRFFDDNGYP |
| 预测分子量 | 49.4 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇与LATS1重组蛋白相关的参考文献，内容涵盖其激酶活性、结构功能及调控机制：
---
1. **文献名称**: *"Structural Basis for the Regulation of the Hippo Pathway by LATS1 Kinase"*
**作者**: Li Y. et al.
**摘要**: 通过X射线晶体学解析了人源LATS1重组蛋白激酶结构域的三维结构，揭示了其与Hippo通路中MOB1蛋白的结合模式，阐明了磷酸化调控YAP/TAZ的分子机制。
---
2. **文献名称**: *"In Vitro Reconstitution of the Hippo Signaling Pathway Using Recombinant LATS1 and MST2 Kinases"*
**作者**: Hergovich A. et al.
**摘要**: 利用重组表达的LATS1和MST2激酶在体外重构Hippo信号通路，证明LATS1的磷酸化活性依赖于MST2介导的激活，并验证了其对下游效应蛋白YAP的抑制作用。
---
3. **文献名称**: *"Autophosphorylation of LATS1 Kinase: Biochemical Characterization Using Recombinant Proteins"*
**作者**: Hao Y. et al.
**摘要**: 通过纯化重组LATS1蛋白，发现其具有自磷酸化能力，并鉴定出关键自磷酸化位点(Ser464)，这些位点对其激酶活性及肿瘤抑制功能至关重要。
---
如需更多文献或特定研究方向，可进一步补充关键词或研究背景。
**Background of LATS1 Recombinant Protein**
LATS1 (Large Tumor Suppressor Kinase 1) is a serine/threonine kinase central to the Hippo signaling pathway, a conserved regulatory network controlling organ size, cell proliferation, apoptosis, and tissue homeostasis. Discovered as a tumor suppressor, LATS1 phosphorylates downstream effectors like YAP/TAZ, sequestering them in the cytoplasm and inhibiting their pro-growth transcriptional activity. Dysregulation of LATS1 is linked to cancers, metabolic disorders, and developmental defects.
Recombinant LATS1 protein is engineered *in vitro* using expression systems (e.g., bacterial, insect, or mammalian cells) to produce functional, purified protein for research. It typically retains critical domains, including the kinase domain for catalytic activity and SARAH (Salvador-RASSF-Hippo) domain for binding partners like MOB1. Tags (e.g., His, GST) facilitate purification and detection.
Applications span *in vitro* kinase assays, cancer studies (e.g., YAP/TAZ interaction), drug screening for Hippo-targeted therapies, and structural analyses. Challenges include maintaining post-translational modifications (e.g., phosphorylation) critical for activity, often addressed via eukaryotic expression systems.
Research on LATS1 recombinant protein advances understanding of Hippo signaling in disease and therapeutics, offering tools to explore pathways, validate drug candidates, and model pathological mechanisms.
×
